Terms: = Colorectal cancer AND BCL6, BCL5, 603, 604, ENSG00000113916, ZBTB27, P41182, LAZ3, BCL6A, ZNF51 AND Clinical Outcome
3 results:
1. Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases.
Zhang C; Wang XY; Zuo JL; Wang XF; Feng XW; Zhang B; Li YT; Yi CH; Zhang P; Ma XC; Chen ZM; Ma Y; Han JH; Tao BR; Zhang R; Wang TQ; Tong L; Gu W; Wang SY; Zheng XF; Yuan WK; Kan ZJ; Fan J; Hu XY; Li J; Zhang C; Chen JH
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759015
[TBL] [Abstract] [Full Text] [Related]
2. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.
Lanza G; Gafà R; Santini A; Maestri I; Guerzoni L; Cavazzini L
J Clin Oncol; 2006 May; 24(15):2359-67. PubMed ID: 16710035
[TBL] [Abstract] [Full Text] [Related]
3. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases.
Durand-Zaleski I; Earlam S; Fordy C; Davies M; Allen-Mersh TG
Cancer; 1998 Sep; 83(5):882-8. PubMed ID: 9731890
[TBL] [Abstract] [Full Text] [Related]
